Enalapril vs Ramipril
## Overview
Enalapril and ramipril are both prodrug ACE inhibitors with landmark trial evidence. Enalapril is the reference standard for HFrEF (CONSENSUS, SOLVD); ramipril is the reference standard for broad cardiovascular protection in high-risk patients (HOPE).
## Mechanism of Action
Both require ester hydrolysis to active diacids (enalaprilat, ramiprilat). Both inhibit ACE, reducing angiotensin II and aldosterone. Ramiprilat has slightly higher ACE affinity than enalaprilat.
## Pharmacokinetics
Enalapril: bioavailability ~60%, enalaprilat half-life ~11 h. Ramipril: bioavailability ~60%, ramiprilat half-life ~13–17 h with tissue binding extending effective duration. Both are renally eliminated.
## Clinical Evidence
CONSENSUS (1987) and SOLVD-Treatment (1991) with enalapril established the mortality benefit of ACEi in HFrEF. HOPE (2000) with ramipril extended the indication to high-risk patients without low EF. Both drugs are considered equivalent for most ACEi indications in guidelines.
## Key Takeaways
- Enalapril: landmark HFrEF trials (CONSENSUS, SOLVD)
- Ramipril: landmark broad CV protection trial (HOPE)
- Both prodrugs with similar PK and efficacy class effects
Veredicto
Enalapril is typically preferred for HFrEF based on the historical CONSENSUS/SOLVD data. Ramipril is preferred for cardiovascular risk reduction in high-risk patients without overt HF. In practice, both are interchangeable for most ACEi indications per current ACC/AHA guidelines.